Clin Cancer Res: The efficacy and safety of preoperative and postoperative application of nivolumab and lirilumab in the treatment of locally recurring squamous cell carcinoma of the head and neck (SCCHN)

Surgery is usually the best treatment for patients with squamous cell carcinoma of the head and neck (SCCHN) that has recurred in a local area
.
Recently, foreign researchers have carried out related studies to evaluate the preoperative and postoperative application of dual immune checkpoint inhibitors [anti PD-1, nivolumab (N) and anti-KIR, lirilumab (L)] for the treatment of locally recurring heads.

Whether patients with squamous cell carcinoma of the neck (SCCHN) can improve disease-free survival (DFS)

Surgery is usually the best treatment for patients with squamous cell carcinoma of the head and neck (SCCHN) that has recurred in a local area

The study is a phase II study.

Patients received nivolumab (240 mg) + lirilumab (240 mg) 7 to 21 days before surgery, followed by 6 adjuvant N + L cycles after surgery.

The study is a phase II study.

The study finally included 28 patients, with a median age of 66 years (range 36-85 years), mainly composed of men (23 cases, 82%), most of whom were currently or previously smokers (24 cases, 86%)

Clinical features

Clinical features Clinical features

The median follow-up time was 22.

8 months (range 9.

The median follow-up time was 22.

Prognostic analysis

Prognostic analysis

ORR was 27 cases (96%; 95% CI, 81.

6 99.

ORR was 27 cases (96%; 95% CI, 81.

Efficacy evaluation

Efficacy evaluation

There was no delay in surgery due to neoadjuvant therapy in the cohort

.

There was no delay in surgery due to neoadjuvant therapy in the cohort

In summary, studies have shown that the preoperative and postoperative application of nivolumab and lirilumab in the treatment of locally recurring head and neck squamous cell carcinoma (SCCHN) patients has a good clinical effect and the toxicity is tolerable and controllable
.
Studies have shown that the preoperative and postoperative application of nivolumab and lirilumab in the treatment of patients with locally recurring squamous cell carcinoma of the head and neck (SCCHN) has a good clinical effect and the toxicity is tolerable and controllable
.
Studies have shown that the preoperative and postoperative application of nivolumab and lirilumab in the treatment of patients with locally recurring squamous cell carcinoma of the head and neck (SCCHN) has a good clinical effect and the toxicity is tolerable and controllable
.

Original source:

Original source:

Hanna GJ, ONeill A, Shin KY, Wong K, Jo VY, Quinn CT, Cutler JM, Flynn M, Lizotte PH, Annino DJ Jr, Goguen LA, Kass JI, Rettig EM, Sethi RKV, Lorch JH, Schoenfeld JD, Margalit DN, Tishler RB, Everett PC, Desai AM, Cavanaugh ME, Paweletz CP, Egloff AM, Uppaluri R, Haddad RI.
Neoadjuvant and Adjuvant Nivolumab and Lirilumab in Patients with Recurrent, Resectable Squamous Cell Carcinoma of the Head and Neck.
Clin Cancer Res .
2021 Oct 19.
doi: 10.
1158/1078-0432.
CCR-21-2635.
Epub ahead of print.
PMID: 34667025.

Hanna GJ, ONeill A, Shin KY, Wong K, Jo VY, Quinn CT, Cutler JM, Flynn M, Lizotte PH, Annino DJ Jr, Goguen LA, Kass JI, Rettig EM, Sethi RKV, Lorch JH, Schoenfeld JD, Margalit DN, Tishler RB, Everett PC, Desai AM, Cavanaugh ME, Paweletz CP, Egloff AM, Uppaluri R, Haddad RI.
Neoadjuvant and Adjuvant Nivolumab and Lirilumab in Patients with Recurrent, Resectable Squamous Cell Carcinoma of the Head and Neck.
Clin Cancer Res .
2021 Oct 19.
doi: 10.
1158/1078-0432.
CCR-21-2635.
Epub ahead of print.
PMID: 34667025.
Leave a message here